Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xylooligosaccharide (XOS) is a prebiotic functional oligosaccharide composed of 2–7 xylose units linked by β-1,4 glycosidic bonds. It is produced from the xylan fraction of plant fiber and is not digestible by human enzymes. Instead, it selectively stimulates the growth of beneficial gut bacteria such as bifidobacteria and lactobacilli in the colon[1][3][5]. XOS has been shown in clinical studies to improve digestive health, regulate blood glucose and lipid levels, enhance immune function, promote mineral absorption (such as calcium), and support overall intestinal microecology[1][3][4][6]. It may also have potential roles in preventing or managing cardiovascular disease, diabetes, hyperlipidemia, hypertension, chronic hepatitis, irritable bowel syndrome (IBS), constipation/diarrhea management, osteoporosis, pruritus and certain cancers[4][6]. Commercially available since the 1980s (originally developed by Suntory in Japan), XOS is now widely used as a dietary supplement ingredient due to its stability under food processing conditions and efficacy at low doses (typically 1–4 g/day)[1][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xylooligosaccharide.